Compare R & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | R | SRRK |
|---|---|---|
| Founded | 1933 | 2012 |
| Country | United States | United States |
| Employees | N/A | 289 |
| Industry | Rental/Leasing Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.8B |
| IPO Year | 1994 | 2018 |
| Metric | R | SRRK |
|---|---|---|
| Price | $270.11 | $56.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $238.56 | $56.17 |
| AVG Volume (30 Days) | 350.6K | ★ 1.5M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ 7.96 | N/A |
| EPS | ★ 2.33 | N/A |
| Revenue | ★ $12,665,000,000.00 | N/A |
| Revenue This Year | $5.00 | N/A |
| Revenue Next Year | $5.05 | $534.24 |
| P/E Ratio | $115.79 | ★ N/A |
| Revenue Growth | ★ 0.23 | N/A |
| 52 Week Low | $157.77 | $27.07 |
| 52 Week High | $284.25 | $58.12 |
| Indicator | R | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 67.12 |
| Support Level | $256.77 | $41.38 |
| Resistance Level | $284.25 | N/A |
| Average True Range (ATR) | 6.97 | 2.45 |
| MACD | -0.63 | 0.52 |
| Stochastic Oscillator | 82.54 | 85.32 |
Ryder System Inc operates in three business segments: (1) Fleet Management Solutions which provides full-service leasing and leasing with flexible maintenance options, commercial rental and maintenance services of trucks, tractors and trailers to customers; (2) Supply Chain Solutions (SCS), which provides integrated logistics solutions, including distribution management, dedicated transportation, transportation management, brokerage, e-commerce, last mile, and professional services; and (3) Dedicated Transportation Solutions (DTS), which provides turnkey transportation solutions in the U.S., including dedicated vehicles, professional drivers, management, and administrative support.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.